ORIGINAL ARTICLES
A Review of Gastrointestinal Stromal Tumours - A Single Centre Experience
Technical Considerations in the Surgical Management of External Laryngotraceal Trauma: Surgical Outcomes

CASE REPORT
Dysphagia Lusoria: A Case Report
Medical Research Symposium & Pacific Partnership in conjunction with
Kuantan Research Day 2016
International Research Network: The Way Forward
ABSTRACTS
Organized by:
Kulliyyah of Medicine, IIUM
Research Management Centre, Kuantan
Abstract ID: 146

Kappa antagonist to prevent drug relapse: Does stage in addiction cycle matter?

Ima Elina Rizwan¹ | Muhammad Harith Zulkifli² | Nur Syafinaz Wasli³ | Syed Mohd Syahmi Syd Mohd Fauzi³

¹Department of Pharmaceutical Chemistry, Kulliyyah of Pharmacy, International Islamic University Malaysia
²Department of Basic Medical Sciences, Kulliyyah of Pharmacy, International Islamic University Malaysia
³Department of Pharmacy Practice, Kulliyyah of Pharmacy, International Islamic University Malaysia

Introduction: An upregulation of the kappa opioid receptor (KOR) system during drug preoccupation stage in addiction cycle will cause dysphoria among addicts which can lead to relapse. Therefore, KOR antagonism treatment might hold the key to prevent relapse. In this study, we aim to identify the exact addiction's stage in which KOR antagonist can be given. Methods: Using a conditioned place preference (CPP) model, adult male Swiss albino mice were divided into two major groups. The first group received treatment at the initial stage of morphine withdrawal (7.5 mg/kg, i.p) while the second group received treatment after complete abstinence was achieved. Each major groups were further divided into two treatment groups (n=8-12), either received a functional KOR antagonist (0.3 mg/kg buprenorphine/ 1 mg/kg naltrexone combination, i.p) or a selective KOR antagonist (10 mg/kg nor-BNI, i.p) prior to morphine priming (2.5 mg/kg, i.p). All data were analyzed using paired sample t-test. Results: The results showed that relapse was successfully attenuated in the groups that received KOR antagonists only after complete abstinence was successfully achieved (not significantly different from their baseline). However, the mice developed unusual sign of behavior sensitization (intermittent freezing, licking) when buprenorphine/naltrexone combination was given at initial stage of withdrawal. Conclusions: Our initial findings suggest that KOR antagonism might be beneficial only after the addicts achieved complete abstinence to prevent future drug-induced relapse. Brain study should be conducted to explain the unusual behavior seen when the drug intervention is given at an earlier stage of withdrawal.

KEYWORDS: drug relapse, kappa antagonist, morphine